131 related articles for article (PubMed ID: 33605950)
1. Nonspecific nuclear uptake of anti-MUC1 aptamers by dead cells: the role of cell viability monitoring in aptamer targeting of membrane-bound protein cancer biomarkers.
Flanagan SP; Fogel R; Edkins AL; Ho LSJ; Limson J
Anal Methods; 2021 Mar; 13(9):1191-1203. PubMed ID: 33605950
[TBL] [Abstract][Full Text] [Related]
2. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059
[TBL] [Abstract][Full Text] [Related]
3. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers.
Ferreira CS; Matthews CS; Missailidis S
Tumour Biol; 2006; 27(6):289-301. PubMed ID: 17033199
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting CD44 and mucin by hyaluronic acid and 5TR1 aptamer for epirubicin delivery into cancer cells: Synthesis, characterization,
Jamshidi Z; Dehghan R; Nejabat M; Abnous K; Taghdisi SM; Hadizadeh F
Heliyon; 2024 Jan; 10(2):e24833. PubMed ID: 38312665
[TBL] [Abstract][Full Text] [Related]
5. In vitro selection of aptamer S1 against MCF-7 human breast cancer cells.
Zhang WY; Chen HL; Chen QC
Bioorg Med Chem Lett; 2019 Aug; 29(16):2393-2397. PubMed ID: 31196711
[TBL] [Abstract][Full Text] [Related]
6. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
[TBL] [Abstract][Full Text] [Related]
7. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours.
Ferreira CS; Papamichael K; Guilbault G; Schwarzacher T; Gariepy J; Missailidis S
Anal Bioanal Chem; 2008 Feb; 390(4):1039-50. PubMed ID: 17694298
[TBL] [Abstract][Full Text] [Related]
8. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
9. A new chemotherapy agent-free theranostic system composed of graphene oxide nano-complex and aptamers for treatment of cancer cells.
Bahreyni A; Yazdian-Robati R; Hashemitabar S; Ramezani M; Ramezani P; Abnous K; Taghdisi SM
Int J Pharm; 2017 Jun; 526(1-2):391-399. PubMed ID: 28495579
[TBL] [Abstract][Full Text] [Related]
10. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes.
Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC
Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795
[TBL] [Abstract][Full Text] [Related]
11. Targeted imaging of breast cancer cells using two different kinds of aptamers -functionalized nanoparticles.
Mohammadinejad A; Taghdisi SM; Es'haghi Z; Abnous K; Mohajeri SA
Eur J Pharm Sci; 2019 Jun; 134():60-68. PubMed ID: 30970280
[TBL] [Abstract][Full Text] [Related]
12. Gold nanoparticle-streptavidin conjugates for rapid and efficient screening of aptamer function in lateral flow sensors using novel CD4-binding aptamers identified through Crossover-SELEX.
Fellows T; Ho L; Flanagan S; Fogel R; Ojo D; Limson J
Analyst; 2020 Aug; 145(15):5180-5193. PubMed ID: 32567629
[TBL] [Abstract][Full Text] [Related]
13. Importance of rigorous in vitro evaluation of prospective cell binding aptamers.
Avci-Adali M; Mludek K; Perle N; Stoll H; Schlensak C; Wendel HP
Nucleic Acid Ther; 2014 Aug; 24(4):250-7. PubMed ID: 25054517
[TBL] [Abstract][Full Text] [Related]
14. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
[TBL] [Abstract][Full Text] [Related]
15. An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.
Liu M; Wang Z; Tan T; Chen Z; Mou X; Yu X; Deng Y; Lu G; He N
Theranostics; 2018; 8(20):5772-5783. PubMed ID: 30555580
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-tagged silver nanoclusters for cell image and Mucin1 detection in vitro.
Zhou L; Wang W; Chen Y; Fan J; Tong C; Liu B
Talanta; 2019 Dec; 205():120075. PubMed ID: 31450473
[TBL] [Abstract][Full Text] [Related]
17. Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting.
Li Z; Hu Y; An Y; Duan J; Li X; Yang XD
Molecules; 2019 Jan; 24(3):. PubMed ID: 30699986
[TBL] [Abstract][Full Text] [Related]
18. Theoretical modeling of masking DNA application in aptamer-facilitated biomarker discovery.
Cherney LT; Obrecht NM; Krylov SN
Anal Chem; 2013 Apr; 85(8):4157-64. PubMed ID: 23480390
[TBL] [Abstract][Full Text] [Related]
19. Molecular Dynamics Simulation Analysis of Anti-MUC1 Aptamer and Mucin 1 Peptide Binding.
Rhinehardt KL; Srinivas G; Mohan RV
J Phys Chem B; 2015 Jun; 119(22):6571-83. PubMed ID: 25963836
[TBL] [Abstract][Full Text] [Related]
20. Direct validation of aptamers as powerful tools to image solid tumor.
Martínez O; Bellard E; Golzio M; Mechiche-Alami S; Rols MP; Teissié J; Ecochard V; Paquereau L
Nucleic Acid Ther; 2014 Jun; 24(3):217-25. PubMed ID: 24490589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
